$LONGBIO-B(01779.HK), $JIANGXI BIO(06915.HK), and $GIANT BIOGENE(02367.HK) placed together: half are waiting for clinical data, while the other half are already making money on shelves. Despite both bearing the 'Biology' label, the gap in commercialization can be a whole body length.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.